ArticleHuman vaccines & immunotherapeutics2021
Risk of Guillain-Barré syndrome following herpes zoster, United States, 2010-2018.
Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- A narrative review of considerations when assessing potential relationships between Guillain-Barré syndrome and vaccines.Human vaccines & immunotherapeutics · 2026Review
- Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in US Medicare Adults Age 65 Years or Older.Drug safety · 2026Article
- Estimating Risk of Guillain-Barré Syndrome in US Medicare-enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-controlled Case Series Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Varicella-zoster virus infection of the central nervous system: clinical features and proteomic analysis of cerebrospinal fluid.Frontiers in cellular and infection microbiology · 2026Article
- Association Between Post-COVID-19 Herpes Zoster Reactivation and Peripheral Nervous System Disorders: Multinational Real-World Evidence from TriNetX.International journal of medical sciences · 2026Article
- Article
- Detection of Herpesviruses (Predominantly HHV-6) in Patients with Guillain-Barré Syndrome.Biomedicines · 2025Article
- Guillain-Barré syndrome after the Zika epidemic in Colombia: A multicenter, matched case-control study.PLoS neglected tropical diseases · 2025Article
- Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017-April 2024.Preventive medicine reports · 2025Article
- Cellular and humoral vaccination response under immunotherapies-German consensus on vaccination strategies in neurological autoimmune diseases.Therapeutic advances in neurological disorders · 2025Article
- Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence.Human vaccines & immunotherapeutics · 2023Review
- Is Guillain-Barre syndrome following chickenpox a parainfectious disease? A case report and literature review.BMC neurology · 2023Review
- The Peculiarity of Infection and Immunity Correlated with Guillain-Barré Syndrome in the HIV-Infected Population.Journal of clinical medicine · 2023Article
- Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults.Human vaccines & immunotherapeutics · 2022Article
- Ascertaining the Kawasaki Disease-Coronavirus Disease 2019 Linkage in a Japanese Administrative Claims Database.Pediatrics international : official journal of the Japan Pediatric SocietyArticle
- Analysis of the incidence status and risk factors for immune-mediated neuropathies: a single-center case-control study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidemiologic data regarding the risk of Guillain-Barré syndrome (GBS) following herpes zoster (HZ) are limited. We conducted a self-controlled case series analysis using two large national data sources to evaluate the risk of GBS following HZ among U.S. adults. We analyzed medical claims from the IBM® MarketScan® Commercial Claims and Encounters (persons 18-64 years during 2010-2018) and Centers for Medicare and Medicaid Services Medicare (persons ≥65 years during 2014-2018) databases. HZ cases were defined as persons with an outpatient claim with a primary or secondary ICD-9 or ICD-10 diagnostic code for HZ. GBS cases were defined as persons with an inpatient claim with a principle diagnostic code for GBS and an associated procedural code. We compared the rates of GBS following HZ in the 1-42-day risk window versus primary (100-365-day) or secondary (43-99-day) control windows. We identified 489,516 persons 18-64 years of age and 650,229 persons ≥65 years of age with HZ, among whom 11 and 41, respectively, developed GBS 1-365 days following HZ. The risk of GBS following HZ was increased during the risk window as compared to the primary control window for both groups, with a rate ratio of 6.3 (95% CI, 1.8-21.9) for those 18-64 years and 4.1 (95% CI, 1.9-8.7) for those ≥65 years. This study provides new and methodologically rigorous epidemiologic support for an association between HZ and GBS, and useful context regarding the benefits versus potential risks of zoster vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.